2018
A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
Foss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNon-Hodgkin lymphomaOverall response rateIntermediate-grade B-cellB cellsPartial responseResponse ratePhase I dose-escalation studyRefractory acute lymphoblastic leukemiaI dose-escalation studyT-cell non-Hodgkin lymphomaB-cell non-Hodgkin lymphomaPositron emission tomography scanSecond-generation purine nucleoside analogAggressive B-cell lymphomasPhase IDose of clofarabineGrade 3 leukopeniaLow-dose cohortMinimal hematologic toxicityRefractory acute leukemiaRefractory low gradeRefractory lymphoid malignanciesSingle-agent rituximab
2006
Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
Choi J, Foss F. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. The Yale Journal Of Biology And Medicine 2006, 79: 169-72. PMID: 17940627, PMCID: PMC1994805.Peer-Reviewed Original ResearchMeSH KeywordsAdenine NucleotidesAdultArabinonucleosidesBone Marrow NeoplasmsClinical Trials as TopicClofarabineDrug Administration ScheduleDrug Resistance, NeoplasmHumansImmunophenotypingLeukemia-Lymphoma, Adult T-CellMaleRecurrenceSkin NeoplasmsStem Cell TransplantationTransplantation, HomologousTreatment OutcomeConceptsLow dose clofarabineLymphoblastic leukemiaAllogeneic stem cell transplantationSignificant clinical activityStem cell transplantationNear complete responseAcute lymphoblastic leukemiaPediatric B-ALLT-cell leukemiaAllogeneic transplantsComplete responsePoor prognosisCell transplantationB-ALLPrecursor TClinical activityNew agentsNovel nucleoside analogueClofarabinePatientsLeukemiaNucleoside analoguesSignificant activityRemissionTransplantation